Zentalis Pharmaceuticals, Inc.
Zentalis Therapeutics (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral WEE1 inhibitor for ovarian cancer and other solid tumors. Its development is focused on Cyclin E1-positive platinum-resistant ovarian cancer, with clinical studies also evaluating… From the company’s description.
In fiscal 2025, Zentalis Pharmaceuticals, Inc. reported a net loss of $137.06M. Operations used $125.25M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zentalis Pharmaceuticals, Inc. does
In the company’s own words
Zentalis Therapeutics (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral WEE1 inhibitor for ovarian cancer and other solid tumors. Its development is focused on Cyclin E1-positive platinum-resistant ovarian cancer, with clinical studies also evaluating azenosertib in combination with bevacizumab for ovarian cancer maintenance therapy. The company holds worldwide development and commercialization rights to azenosertib through ownership and an exclusive license. Zentalis has no products approved for commercial sale and relies on contract manufacturers to supply its clinical candidates. Its clinical program includes the Phase 2 DENALI study and the Phase 3 ASPENOVA study in Cyclin E1-positive ovarian cancer, as well as the Phase 1b MUIR combination study. The company has no reportable business segments described; its activities center on azenosertib research and development. Its registered trademark is ZENTALIS. Its website is www.zentalis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1725160
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zentalis Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Zentalis Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zentalis Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zentalis Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zentalis Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”